LL-37
Also known as: Cathelicidin, Cathelicidin antimicrobial peptide, hCAP-18
Human antimicrobial peptide with broad-spectrum activity against bacteria, fungi, and viruses.
Evidence
Emerging
FDA status
Not FDA-approved
Source
Naturally occurring human cathelicidin, synthesized therapeutically
Overview
Human antimicrobial peptide with broad-spectrum activity against bacteria, fungi, and viruses.
Mechanism of Action
Disrupts microbial membranes via carpet-like mechanism, binds LPS to neutralize endotoxins and block TLR4, inhibits biofilm formation, exhibits immunomodulatory effects through chemokine induction, promotes wound healing via TGF-β pathway.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Broad-spectrum antimicrobial activity
- Anti-biofilm effects
- Neutralizes bacterial endotoxins
- Promotes wound healing
- Modulates immune response
- Antiviral effects
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. LL-37 isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Extensive in vitro and preclinical studies, limited human trials
Antimicrobial effects are well described in the lab. Human data are limited to small early trials, such as for leg ulcers.
Safety Information
Potential Side Effects
- •Injection site reactions
- •Local irritation
- •Cell toxicity in lab studies
Contraindications
- Pregnancy
- Breastfeeding
Interactions
- ⚠Unknown